GURUFOCUS.COM » STOCK LIST » Latin America » Mexico » MEX » InflaRx NV (MEX:IFRX) » Definitions » Pretax Margin %
Switch to:

InflaRx NV (MEX:IFRX) Pretax Margin %

: % (As of Sep. 2022)
View and export this data going back to 2018. Start your Free Trial

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. InflaRx NV's Pre-Tax Income for the three months ended in Sep. 2022 was MXN-157.41 Mil. InflaRx NV's Revenue for the three months ended in Sep. 2022 was MXN0.00 Mil. Therefore, InflaRx NV's pretax margin for the quarter that ended in Sep. 2022 was %.

The historical rank and industry rank for InflaRx NV's Pretax Margin % or its related term are showing as below:



InflaRx NV Pretax Margin % Historical Data

The historical data trend for InflaRx NV's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InflaRx NV Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Pretax Margin %
Premium Member Only Premium Member Only - - - - -

InflaRx NV Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Pretax Margin % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

InflaRx NV Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

InflaRx NV's Pretax Margin for the fiscal year that ended in Dec. 2021 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2021 )/Revenue (A: Dec. 2021 )
=-1078.9303728814/0
= %

InflaRx NV's Pretax Margin for the quarter that ended in Sep. 2022 is calculated as

Pretax Margin=Pre-Tax Income (Q: Sep. 2022 )/Revenue (Q: Sep. 2022 )
=-157.41170871287/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InflaRx NV  (MEX:IFRX) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


InflaRx NV Pretax Margin % Related Terms

Thank you for viewing the detailed overview of InflaRx NV's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


InflaRx NV (MEX:IFRX) Business Description

InflaRx NV logo
Traded in Other Exchanges
Address
Winzerlaer Strasse 2, Jena, DEU, 07745
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

InflaRx NV (MEX:IFRX) Headlines

Other Sources